Literature DB >> 15490063

Bone mineral density in menopausal women with primary hyperparathyroidism before and after parathyroidectomy.

Antonio Sitges-Serra1, Meritxell Girvent, José A Pereira, Jaime Jimeno, Xavier Nogués, Francisco J Cano, Joan J Sancho.   

Abstract

The relationship between osteoporosis and primary hyperparathyroidism (pHPT) has not been definitely established because both diseases occur predominantly in postmenopausal women, and because PTH has a paradoxical effect on bone. We have investigated the prevalence of reduced bone mineral density (BMD) in women with pHPT, its relationship with metabolic parameters, and its course after parathyroidectomy. A prospective observational study was carried out on perimenopausal and postmenopausal women consecutively diagnosed and operated on for pHPT. Demographic data were recorded, as well as, PTH, Ca, calciuria/24h, P, vitamin D, adenoma weight. The BMD was measured at three sites: femoral neck (FN), proximal femur (PF), and lumbar spine (LS). Fifty-two patients were included with a mean age of 61+/-12 years. The prevalence of reduced BMD (< or = 1SD, T-score) was 80%-100% depending on site. Parathyroid hormone was higher in patients with osteoporosis (319+/-181 pg/ml) than in those with osteopenia (230+/-83 pg/ml) or normal BMD (148+/-81 pg/ml;p < 0,04). Twenty-eight patients were investigated 1 year after parathyroidectomy. The BMD improved significantly at all sites, particularly in patients with osteoporosis. Age correlated inversely with BMD increases at the femoral sites (r= -0,47;p = 0,02) but not at the LS. 25-OHD3 plasma levels correlated inversely with BMD increases at PF (r= -0,76; p < 0,0001). In pHPT, there is a high prevalence of BMD abnormalities. No metabolic variables had a definite influence on BMD values but a tendency was observed for lower BMD in severe pHPT. One year after parathyroidectomy, there were significant BMD increases that were more marked at femoral sites, in younger patients, in patients with preoperative osteoporosis, and in those with lower plasma levels of 25-OHD3.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15490063     DOI: 10.1007/s00268-004-7562-6

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  16 in total

Review 1.  The aging process as a modifier of metabolism.

Authors:  R M Russell
Journal:  Am J Clin Nutr       Date:  2000-08       Impact factor: 7.045

Review 2.  Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century.

Authors:  John P Bilezikian; John T Potts; Ghada El-Hajj Fuleihan; Michael Kleerekoper; Robert Neer; Munro Peacock; Jonas Rastad; Shonni J Silverberg; Robert Udelsman; Samuel A Wells
Journal:  J Clin Endocrinol Metab       Date:  2002-12       Impact factor: 5.958

Review 3.  Parathyroid hormone for treatment of osteoporosis.

Authors:  Carolyn Crandall
Journal:  Arch Intern Med       Date:  2002-11-11

4.  Primary hyperparathyroidism: bone structure, balance, and remodeling before and 3 years after surgical treatment.

Authors:  T Steiniche; P Christiansen; A Vesterby; R Ullerup; I Hessov; L E Mosekilde; F Melsen
Journal:  Bone       Date:  2000-05       Impact factor: 4.398

5.  Multifactorial risk profile for bone fractures in primary hyperparathyroidism.

Authors:  Erik Nordenström; Johan Westerdahl; Birger Lindergård; Pia Lindblom; Anders Bergenfelz
Journal:  World J Surg       Date:  2002-09-26       Impact factor: 3.352

6.  Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism.

Authors:  P Vestergaard; C L Mollerup; V G Frøkjaer; P Christiansen; M Blichert-Toft; L Mosekilde
Journal:  BMJ       Date:  2000-09-09

7.  [Prevalence of osteoporosis assessed by densitometry in the Spanish female population].

Authors:  M Díaz Curiel; J J García; J L Carrasco; J Honorato; R Pérez Cano; A Rapado; C Alvarez Sanz
Journal:  Med Clin (Barc)       Date:  2001-01-27       Impact factor: 1.725

8.  A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery.

Authors:  S J Silverberg; E Shane; T P Jacobs; E Siris; J P Bilezikian
Journal:  N Engl J Med       Date:  1999-10-21       Impact factor: 91.245

Review 9.  Differential effects of intermittent and continuous administration of parathyroid hormone on bone histomorphometry and gene expression.

Authors:  Sutada Lotinun; Jean D Sibonga; Russell T Turner
Journal:  Endocrine       Date:  2002-02       Impact factor: 3.633

10.  Forearm bone density in primary hyperparathyroidism: long-term follow-up with and without parathyroidectomy.

Authors:  D Sudhaker Rao; Elizabeth A Wallace; Rosella F Antonelli; Gary B Talpos; Mohammed R Ansari; Gordon Jacobsen; George W Divine; A Michael Parfitt
Journal:  Clin Endocrinol (Oxf)       Date:  2003-03       Impact factor: 3.478

View more
  4 in total

1.  The impact of parathyroidectomy on serum ADAMTS1, ADAMTS4 levels, insulin resistance, and subclinical cardiovascular disease in primary hyperparathyroidism.

Authors:  Melia Karakose; Mustafa Caliskan; Muyesser Sayki Arslan; Taner Demirci; Suleyman Karakose; Erman Cakal
Journal:  Endocrine       Date:  2016-11-14       Impact factor: 3.633

Review 2.  What symptom improvement can be expected after operation for primary hyperparathyroidism?

Authors:  Nadine R Caron; Janice L Pasieka
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

3.  [Metabolic bone diseases].

Authors:  F Jakob
Journal:  Internist (Berl)       Date:  2007-10       Impact factor: 0.743

4.  Gender differences in bone mineral density in patients with sporadic primary hyperparathyroidism.

Authors:  Danica M Vodopivec; Angelica M Silva; Dinamarie C Garcia-Banigan; Ioannis Christakis; Ashley Stewart; Kelly Schwarz; Caroline S Hussey; Roland Bassett; Mimi I Hu; Nancy D Perrier
Journal:  Endocrinol Diabetes Metab       Date:  2018-09-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.